A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice

• Published in: Vaccine Vol. 40; no. 8; pp. 1162 - 1169
• Main Authors: Lazo, Laura, Bequet-Romero, Monica, Lemos, Gilda, Musacchio, Alexis, Cabrales, Ania, Bruno, Andy J., Ariel Espinosa, Luis, Saloheimo, Markku, Vitikainen, Marika, Hernández, Amalia, Emalfarb, Mark, Tchelet, Ronen, Suzarte, Edith, Guillén, Gerardo
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 16.02.2022; Elsevier Limited
• Subjects: Amino acids; Animals; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Binding; Biotechnology; Core protein; Coronaviruses; COVID; COVID-19; COVID-19 Vaccines; Disease transmission; Enzymes; Fungi; Genetic engineering; Hepatitis B; HIV; Human immunodeficiency virus; Humans; Immune response; Immune response (cell-mediated); Immune response (humoral); Immune system; Immunity, Cellular; Immunogenicity; Mice; Mice, Inbred BALB C; Pandemics; Protein; Proteins; Public health; Receptors; SARS CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus; Vaccine; Vaccines; Viral diseases; Cuba; COVID; SARS CoV-2; Vaccine; Immunogenicity; Protein; C1
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2022.01.007

Since the beginning of the COVID-19 pandemic, the development of effective vaccines against this pathogen has been a priority for the scientific community. Several strategies have been developed including vaccines based on recombinant viral protein fragments. The receptor-binding domain (RBD) in the S1 subunit of S protein has been considered one of the main targets of neutralizing antibodies. In this study we assess the potential of a vaccine formulation based on the recombinant RBD domain of SARS-CoV-2 expressed in the thermophilic filamentous fungal strain Thermothelomyces heterothallica and the hepatitis B virus (HBV) core protein. Functional humoral and cellular immune responses were detected in mice. To our knowledge, this is the first report on the immune evaluation of a biomedical product obtained in the fungal strain T. heterothallica. These results together with the intrinsic advantages of this expression platform support its use for the development of biotechnology products for medical purpose.